Pontocerebellar Hypoplasia
Ponoteocerebellar hypoplasia (PCH) is a group of rare autosomal recessive neurodegenerative disorders with a prenatal onset, characterized by hypoplasia in addition to varying degrees of atrophy of the cerebellum and brainstem. MRI findings include a small cerebellum and brainstem, variable neocortical atrophy, severe and progressive microcephaly and variable ventriculomegaly. Clinically, most patients have severe intellectual disability, swallowing problems, and seizures.

Cerebellar Vermis Hypoplasia
Cerebellar Vermis Hypoplasia (CVH) consists of isolated vermis hypoplasia and may also be called “Dandy-Walker variant” due to the phenotypic overlap with Dandy-Walker malformation (DWM). DWM includes vermis hypoplasia in addition to several other features such as enlarged posterior fossa.

Our Cerebellar/Pontocerebellar Hypoplasia Sequencing Panel includes analysis of the 27 genes listed below. Our Cerebellar/Pontocerebellar Hypoplasia Deletion/Duplication Panel includes analysis of the 24 genes listed below in bold.

<table>
<thead>
<tr>
<th>Cerebellar/Pontocerebellar Hypoplasia Panel Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMPD2</td>
</tr>
<tr>
<td>CASK</td>
</tr>
<tr>
<td>CDK5</td>
</tr>
<tr>
<td>CHMP1A</td>
</tr>
<tr>
<td>CLP1</td>
</tr>
<tr>
<td>EXOSC3</td>
</tr>
<tr>
<td>EXOSC8</td>
</tr>
</tbody>
</table>

Disorder and Associated Genes

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Gene</th>
<th>Clinical Features / Molecular Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCH type 1</td>
<td>AMPD2, OPHN1, TBC1D23, TUBA8</td>
<td>PCH type 1 is characterized by loss of motor neurons in the spinal cord, which is morphologically similar to the hereditary spinal muscular atrophies, in addition to the typical findings of PCH. Renbaum et al. (2009) identified a homozygous nonsense mutation in VRK1 in a consanguineous family with PCH type 1. VRK1 encodes a serine-threonine kinase which is thought to play a role in nervous system development and neuronal maintenance. Wan et al. (2012) identified homozygous and compound heterozygous mutations in EXOSC3 in affected members of nine families with PCH type 1B. EXOSC3 is a core component of the human RNA exosome complex. Boczonadi et al. (2014) identified homozygous EXOSC8 mutations in 22 infants from three families with cerebellar and corpus callosum hypoplasia, abnormal CNS myelination or spinal motor neuron disease. EXOSC8 is a core component of the human RNA exosome complex.</td>
</tr>
<tr>
<td>PCH type 2</td>
<td>TSEN54, TSEN34, TSEN2, TSEN15, TSEN34, TSEN15, TSEN34</td>
<td>PCH type 2 is characterized by dyskinesia and dystonia and is the most common subtype of PCH. Mutations in TSEN54, TSEN2 and TSEN34 are associated with PCH type 2. TSEN54 encodes one of the noncatalytic subunits of the RNA splicing endonuclease complex, and TSEN2 and TSEN34 encode catalytic subunits of the RNA splicing endonuclease. This complex has a high abundance of its mRNA in the developing pons, cerebellar dentate and olivary nuclei, suggesting it is importance for the development of these brain areas. Budde et al. (2008) sequenced the TSEN54, TSEN2 and TSEN34 genes in 52 patients with PCH type 2, and identified a common TSEN54 missense mutation (p.A307S) in the homozygous state in 47/52 patients, a homozygous missense mutation in TSEN2 one patient, and a homozygous missense mutation in TSEN34 in one other patient. Homozygous or compound heterozygous missense mutations in the SEPSECS gene have been identified in 4 unrelated patients of Iraqi or Iraqi/Moroccon descent with cerebellocerebral atrophy, profound intellectual disability and spasticity most consistent with pontocerebellar hypoplasia type 2. Homozygous mutations in TSEN15 have been reported in patients with PCH type 2F from</td>
</tr>
<tr>
<td>PCH type</td>
<td>Associated with</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------</td>
<td>-------------</td>
</tr>
<tr>
<td>3</td>
<td>[OMIM#608027]</td>
<td>A homozygous truncating variant in the PCLO gene has been described in a consanguineous family with multiple affected individuals with pontocerebellar hypoplasia.</td>
</tr>
<tr>
<td>PCLO</td>
<td>[OMIM#604918]</td>
<td>PCH type 4, also known as fatal infantile olivopontocerebellar hypoplasia, has clinical overlap with PCH type 2, however it has a more severe course and is often associated with early postnatal death. The findings of polyhydramnios and contractures have been described prenatally in some cases of PCH type 4. Budde et al. (2008) sequenced the TSEN54 gene in 3 patients with PCH type 4, and identified homozygous mutations in all patients.</td>
</tr>
<tr>
<td>TSEN54</td>
<td>[OMIM#608755]</td>
<td>Characteristic features of PCH type 6 include cerebral atrophy, hypotonia, convulsions and multiple respiratory chain defects. Edwardson et al. (2007) identified an intrinsic mutation in the RARS2 gene in a consanguineous family with PCH type 6. RARS2 encodes for a mitochondrial arginine tRNA synthetase and plays a role in protein synthesis and RNA processing, however the underlying mechanism of disease is not well understood. Namavar et al. (2011) identified 2 patients with RARS2 mutations out of a cohort of 169 patients referred for molecular testing for PCH of varying subtypes.</td>
</tr>
<tr>
<td>RARS2</td>
<td>[OMIM#611524]</td>
<td>Biallelic mutations in the TOE1 gene have been observed in multiple unrelated families with PCH type 7.</td>
</tr>
<tr>
<td>TOE1</td>
<td>[OMIM#613931]</td>
<td>PCH type 8 is characterized by severe psychomotor retardation, abnormal movements, hypotonia, spasticity and variable visual defects. Brain MRI show pontocerebellar hypoplasia, decreased cerebral white matter and a thin corpus callosum. Mochida et al. (2012) identified 2 different homozygous mutations in CHMP1A in families with PCH type 9.</td>
</tr>
<tr>
<td>CHMP1A</td>
<td>[OMIM#164010]</td>
<td>In 5 families with pontocerebellar hypoplasia type 9, Akizu et al. (2013) identified 5 different homozygous mutations in the AMPD2 gene. Brain MRI showed a unique finding which was present on axial images in which the brainstem takes on a “figure 8” appearance, with relative preservation of the cerebellar vermis. There was also generalized atrophy of the cerebral cortex and severe corpus callosum hypoplasia. Mutations causing premature truncation as well as missense mutations of highly conserved amino acid residues have been reported.</td>
</tr>
<tr>
<td>AMPD2</td>
<td>[OMIM#102771]</td>
<td>The same homozygous missense mutation, R140H, was identified in affected family members of 9 consanguineous Turkish families. Haplotype analysis indicated this change as a founder mutation. Affected individuals presented with motor-sensory defects, macrocephaly, spasticity, seizures and inability to walk. Imaging of the brain showed variable abnormalities including cortical dysgenesis, pontocerebellar atrophy or hypoplasia, and thin corpus callosum. In vitro functional studies suggest that the mutation causes loss of tRNA splicing endonuclease (TSEN) complex function, resulting in accumulation of unprocessed pre-tRNAs.</td>
</tr>
<tr>
<td>PCH type 10</td>
<td>[OMIM#615803]</td>
<td>The same homozygous missense mutation, R140H, was identified in affected family members of 9 consanguineous Turkish families. Haplotype analysis indicated this change as a founder mutation. Affected individuals presented with motor-sensory defects, macrocephaly, spasticity, seizures and inability to walk. Imaging of the brain showed variable abnormalities including cortical dysgenesis, pontocerebellar atrophy or hypoplasia, and thin corpus callosum. In vitro functional studies suggest that the mutation causes loss of tRNA splicing endonuclease (TSEN) complex function, resulting in accumulation of unprocessed pre-tRNAs.</td>
</tr>
<tr>
<td>CLP1</td>
<td>[OMIM#608757]</td>
<td>MIC-PCH is associated with mutations in the CASK gene and is characterized by severe or profound intellectual disability and structural brain anomalies including congenital progressive microcephaly, simplified gyral pattern, thin brain stem with flattening of the pons, and severe cerebellar hypoplasia in females. Seizures, sensorineural hearing loss and retinal anomalies (optic disk pallor/optic nerve hypoplasia) may also be present. Mutations associated with MIC-PCH are typically de novo and are thought to be lethal in males. Milder, familial mutations have also been described that are associated with mild to moderate intellectual disability in males, and no symptoms in carrier females. CASK encodes a calcium/calmodulin-dependent serine protein kinase and functions in both pre- and post-synaptic sites as part of large signaling complexes. Tarpey et al. (2009) identified CASK mutations in 4/46 individuals with MIC-PCH.</td>
</tr>
<tr>
<td>CASK</td>
<td>[OMIM#300172]</td>
<td>Mutations in the OPHN1 gene have been identified in patients with X-linked Mental Retardation with Cerebellar Hypoplasia. In patients with OPHN1 mutations, magnetic resonance imaging (MRI) may also reveal cerebral atrophy and ventriculomegaly. Physical findings typically include tall stature, macrocephaly, and common facial features such as deep-set eyes, long tubular nose, short philtrum, thin upper lip and prominent chin. Other features may include seizures, ocuolomotor problems, dysmetria, adiadochokinesia, hyperactivity, and anxiety. Most heterozygous females have mild cognitive handicaps. OPHN1 is highly expressed in fetal brain tissue and is postulated to affect cell migration and outgrowth of axons and dendrites. Philip et al. (2003) reported that 2/6 (33%) males with moderate mental retardation and...</td>
</tr>
</tbody>
</table>

---

dnatesting.uchicago.edu • 773-834-0555
The analysis of the panel genes is performed by oligonucleotide array CGH. Partial exonic copy number changes and rearrangements of less than 400 bp may not be detected by array-CGH. Array-CGH will not detect low-level mosaicism, balanced translocations, inversions, or point mutations that may be responsible for the clinical phenotype. The sensitivity of this assay may be reduced when DNA is extracted by an outside laboratory.

Inheritance:
AMPD2, CDK5, CHMP1A, CLP1, EXOSC3, EXOSC8, PCLO, RARS2, RELN, SEPSECS, TBC1D23, TOE1, TSEN15, TSEN2, TSEN34, TSEN54, TUBA8, VLDLR, and VPSS3, VRK1 mutations are inherited in an autosomal recessive pattern. Parents of an affected child are most likely obligate carriers. Recurrence risk for carrier parents is 25%.

De novo mutations described to date have been de novo in nature. The recurrence risk for parents is less than 1%, based on the theoretical risk for germline mosaicism. Both de novo and inherited mutations in TUBB3 have been described. The recurrence risk for unaffected parents of an isolated case is <1%. The recurrence risk for affected parents is 50%.

CASK mutations associated with MIC-PCH are typically de novo in females and thought to be lethal in males. Recurrence risk for parents of an affected child is <1% for de novo mutations, based on the risk of gonadal mosaicism. Milder CASK mutations can be associated with mild to moderate intellectual disability in males, and carrier females may be asymptomatic. Recurrence risk for a carrier female is 50% in a male child.

Mutations in OPHN1 are inherited in an X-linked pattern and result in clinical features in affected males and females. Males are more severely affected than females. A woman who has more than one affected son is an obligate carrier. Recurrence risk for carrier mothers is 50%.

Test methods:
Comprehensive sequence coverage of the coding regions and splice junctions of all genes in this panel is performed. Targets of interests are enriched and prepared for sequencing using the Agilent SureSelect system. Sequencing is performed using Illumina technology and reads are aligned to the reference sequence. Variants are identified and evaluated using a custom collection of bioinformatic tools and comprehensively interpreted by our team of directors and genetic counselors. All pathogenic and likely pathogenic variants are confirmed by Sanger sequencing. The technical sensitivity of this test is estimated to be >99% for single nucleotide changes and insertions and deletions of less than 20 bp.

Deletion/duplication analysis of the panel genes is performed by oligonucleotide array-CGH. Partial exonic copy number changes and rearrangements of less than 400 bp may not be detected by array-CGH. Array-CGH will not detect low-level mosaicism, balanced translocations, inversions, or point mutations that may be responsible for the clinical phenotype. The sensitivity of this assay may be reduced when DNA is extracted by an outside laboratory.
Cerebellar/Pontocerebellar Hypoplasia Sequencing Panel (27 genes sequencing)

Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
Cost: $2800
CPT codes: 81407
Turn-around time: 8 weeks

Note: We cannot bill insurance for the above test.

Cerebellar/Pontocerebellar Hypoplasia Deletion/Duplication Panel (24 genes deletion/duplication analysis)

Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
Cost: $2,500
CPT codes: 81407
Turn-around time: 6 weeks

Results:
Results, along with an interpretative report, will be faxed to the referring physician. Additional reports will be provided as requested. All abnormal results will be reported by telephone.

For more information about our testing options, please visit our website at dnatesting.uchicago.edu or contact us at 773-834-0555.

References:


Committed to CUSTOMIZED DIAGNOSTICS, TRANSLATIONAL RESEARCH & YOUR PATIENTS’ NEEDS